We are live on
!
Find out more
NR
Newfound Research Portfolio holdings
AUM
$40.8M
1-Year Est. Return
12.42%
This Fund
S&P 500
This Quarter
Est. Return
+9.53%
1 Year Est. Return
-12.42%
3 Year Est. Return
+54.59%
5 Year Est. Return
+89.01%
10 Year Est. Return
–
AUM
$82.8M
AUM Growth
+$21.1M
(+34%)
Cap. Flow
+$15M
Cap. Flow
% of AUM
18.13%
Top 10 Holdings %
Top 10 Hldgs %
77.75%
Holding
141
New
20
Increased
82
Reduced
20
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$4.9M |
| 2 |
iShares MSCI USA Momentum Factor ETF
MTUM
|
+$1.63M |
| 3 |
Vanguard US Momentum Factor ETF
VFMO
|
+$1.62M |
| 4 |
Fidelity Momentum Factor ETF
FDMO
|
+$1.25M |
| 5 |
JPMorgan US Momentum Factor ETF
JMOM
|
+$1.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$276K |
| 2 |
Synopsys
SNPS
|
+$103K |
| 3 |
Accenture
ACN
|
+$100K |
| 4 |
Danaher
DHR
|
+$86K |
| 5 |
Costco
COST
|
+$86K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 83.3% |
| 2 | Technology | 3.96% |
| 3 | Healthcare | 3.19% |
| 4 | Consumer Staples | 3.13% |
| 5 | Industrials | 2.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
126
Costco
COST
$415B
| – | – |
-192
| Closed | -$86K |
|
|
127
Danaher
DHR
$152B
| – | – |
-319
| Closed | -$86K |
|
128
Edwards Lifesciences
EW
$51.8B
| – | – |
-564
| Closed | -$64K |
|
|
GRMN
129
Garmin
GRMN
$55.9B
| – | – |
-395
| Closed | -$61K |
|
130
IDEX
IEX
$17.2B
| – | – |
-343
| Closed | -$71K |
|
131
Intuit
INTU
$95.2B
| – | – |
-126
| Closed | -$68K |
|
132
Intuitive Surgical
ISRG
$130B
| – | – |
-249
| Closed | -$83K |
|
133
Keysight
KEYS
$55.5B
| – | – |
-508
| Closed | -$83K |
|
134
NVIDIA
NVDA
$5.52T
| – | – |
-3,240
| Closed | -$67K |
|
135
ResMed
RMD
$34B
| – | – |
-260
| Closed | -$69K |
|
136
Republic Services
RSG
$67.1B
| – | – |
-678
| Closed | -$81K |
|
|
137
Synopsys
SNPS
$89B
| – | – |
-344
| Closed | -$103K |
|
138
Teleflex
TFX
$5.84B
| – | – |
-188
| Closed | -$71K |
|
139
West Pharmaceutical
WST
$24.4B
| – | – |
-162
| Closed | -$69K |
|
140
Zoetis
ZTS
$31B
| – | – |
-408
| Closed | -$79K |
|
|
INFO
141
DELISTED
IHS Markit Ltd. Common Shares
INFO
| – | – |
-509
| Closed | -$59K |
|
Similar funds
AM
PSCM
HLC
LCM
MCMI
OMS
SEM
PIM
Newfound Research's Q4 2021 Portfolio in Review
As of Q4 2021, Newfound Research held 141 positions worth $82.8M, up 34% from $61.8M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Newfound Research deployed $15M of net new capital in Q4 2021, opening 20 new positions and adding to 82 existing holdings. Its largest new stake was Union Pacific: 536 shares worth $135K.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 83% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $276K trimmed.
- Newfound Research's largest Q4 2021 buy was Union Pacific: 536 shares worth $135K.
- Newfound Research added most to Vanguard S&P 500 ETF in Q4 2021, an estimated $4.9M increase.
- Newfound Research's biggest Q4 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $276K.
- Newfound Research fully exited Synopsys in Q4 2021, selling an estimated $103K.
- Newfound Research's ten largest holdings make up 78% of its $82.8M portfolio in Q4 2021.
- Newfound Research opened 20 new positions and closed 19 in Q4 2021.
- Newfound Research's portfolio value rose 34% quarter-over-quarter to $82.8M.
Based on Newfound Research's 13F filing for Q4 2021, filed 19 Jan 2022.